---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-103598"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2022-04-13T23:59:59+00:00"
generated_at: "2026-06-26T07:43:28.315477+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology appoints Jotin Marango as CFO and Head of Corporate Development

## Summary
- Dr. Marango will assume CFO role effective April 25, 2022, succeeding interim CFO Mark Manfredi.
- Base salary of $425,000; annual bonus target of 40% of base salary.
- Granted option to purchase 397,199 shares, vesting 25% on one-year anniversary and rest over 36 months.
- Dr. Marango previously served as SVP, CFO and CBO at Aptose Biosciences.
- Severance benefits include lump-sum payments and accelerated vesting upon qualifying termination.

## SEC filing metadata
- accession: 0001193125-22-103598
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2022-04-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312522103598/0001193125-22-103598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312522103598/d323540d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-103598
- JSON: https://secwatch.observer/filing/0001193125-22-103598.json
- Plain text: https://secwatch.observer/filing/0001193125-22-103598.txt

## Key facts
- Executive change
  Jotin Marango was appointed as Chief Financial Officer, Head of Corporate Development at ImageneBio, Inc..
  - Action: appointed
  - Role: Chief Financial Officer, Head of Corporate Development
  source text: appoint Jotin Marango, M.D., Ph.D. as Chief Financial Officer, Head of Corporate Development, effective April 25, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312522103598/0001193125-22-103598-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.